Sertraline Medication Review Checklist for Ongoing Care

Reconfirm the reason for treatment

Records can drift toward a medicine name while the original diagnosis and goals disappear. Restate the condition being treated, the symptoms that mattered at baseline, and which functions were expected to improve.

Compare change rather than asking only if it works

Review mood, anxiety, sleep, panic, compulsions, trauma symptoms, cycle-linked symptoms, daily function, adherence, and adverse effects as relevant. A broad yes or no can hide improvement in one area and deterioration in another.

Update the interaction picture

Add new prescriptions, nonprescription pain relievers, cough products, supplements, recently stopped medicines, and substances. Recheck contraindications, serotonin risk, bleeding concern, and other warnings when the list changes.

Use refill review to protect continuity

Confirm supply, pharmacy, follow-up date, prescriber ownership, and what happens if the refill cannot be approved immediately. Avoid both automatic continuation without safety review and avoidable abrupt interruption.

Know when routine review is not enough

Suicidal intent, a seizure, severe confusion, a severe allergic reaction, serious bleeding, or a rapidly escalating behavioral change needs urgent assessment. A checklist is a record aid, not a crisis pathway.

Prescription status and the diagnostic boundary

Sertraline is a prescription medicine. Researching sertraline medication review can prepare an adult for a clinical visit, but it cannot confirm a diagnosis or establish that this medicine is appropriate. The prescriber still needs a symptom timeline, functional impact, previous treatment, relevant medical history, pregnancy considerations when applicable, allergies, substance use, and a candid account of mood and behavioral changes.

The current DailyMed label lists major depressive disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder among its indications. Those labels describe different clinical patterns. A clinician must distinguish them from bipolar disorder, medicine or substance effects, medical illness, grief, and other explanations before a treatment choice is made.

Contraindications and interaction details to disclose

The checked label lists monoamine oxidase inhibitor use within the defined separation period, pimozide, and known hypersensitivity to sertraline among the contraindication boundaries. Other serotonergic products can raise serotonin-syndrome concern. Aspirin, nonsteroidal anti-inflammatory drugs, antiplatelet medicines, warfarin, and other anticoagulants can add bleeding risk.

Bring exact names for prescriptions, nonprescription pain or cold medicines, supplements, recently stopped products, alcohol, cannabis, stimulants, and other substances. A pharmacy list is useful but may be incomplete. Do not stop another prescribed medicine to make the list look safer; let the prescriber and pharmacist interpret the complete record.

Side effects, monitoring, and urgent care

Commonly reported effects can involve the stomach or bowel, sleep, sweating, tremor, fatigue, appetite, or sexual function. Their timing, persistence, severity, and effect on daily life determine whether routine advice is enough. Follow-up should also ask directly about clinical worsening, suicidal thinking, agitation, unusual energy, reduced need for sleep, impulsivity, confusion, and newly added medicines.

Use urgent help for suicidal intent, a seizure, severe confusion, serious allergic swelling or breathing difficulty, significant bleeding, or a rapidly escalating behavioral change. Fever with marked agitation, muscle rigidity, or coordination change can signal a serious serotonin-related reaction. A standard portal message is not an emergency response.

Build a record that supports the next decision

Keep a concise record of the working diagnosis, the original symptoms and functional goals, the current prescription, missed doses, unwanted effects, new medicines, and the agreed follow-up route. Record what has changed instead of relying on a broad statement that treatment feels better or worse. This makes routine review, transfer between clinicians, pharmacy questions, and refill decisions safer and more specific.

Do not share tablets, restart an old prescription, conceal another product, or make an abrupt change from a general web guide. The prescriber should guide routine changes. Serious or rapidly worsening symptoms move the decision out of routine follow-up and into urgent assessment.

Ongoing review record

Where this page fits in the sertraline pathway